膜杰作
Star Staining
描述（Description）
The Human FGF-21 (Luc) HEK293 Reporter Cell was engineered to not only express SRE signaling response element, but also express the receptor human Klotho beta (Gene ID: 152831). When stimulated with human FGF-21 protein, receptor-mediated signaling can drive SRE-mediated luminescence.
应用说明（Application）
• Bioactivity detection of human FGF-21 fusion protein.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
培养基（Culture Medium）
DMEM + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Expression analysis of human Klotho beta on Human FGF-21 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human FGF-21 (Luc) HEK293 Reporter Cell or negative control cell using anti-human Klotho beta antibody followed by staining with PE anti-human IgG antibody.
Protocol
Signaling Bioassay
Response to human FGF-21 protein (RLU).
The Human FGF-21 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human FGF-21 protein (Cat.No.FG1-H5243). The EC50 was approximately 0.29 μg/mL.
Protocol
Response to human FGF-21 protein (FOLD).
The Human FGF-21 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human FGF-21 protein (Cat.No.FG1-H5243). The max induction fold was approximately 3.59.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human FGF-21 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human FGF-21 protein (Cat.No.FG1-H5243). Human FGF-21 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 5-22.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.
License Disclosure
This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
